Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Advocacy
Trade group: BioShield II bill needed, but without patent extensions
November 18th, 2005
The Coalition for a Competitive Pharmaceutical Market (CCPM) said the excessive patent extensions and market exclusivities being considered in Senate BioShield legislation would drive up healthcare costs for employers, health insurers, and consumers. To highlight its concerns with this legislation, which CCPM says contains harmful intellectual property (IP) provisions, CCPM is running print ads in the Washington, DC market. "The more we learn about the vast and deadly impact a bioterrorist attack or pandemic could have on our nation, the more apparent it becomes that America urgently needs a solution to biodefense preparedness. The good news is that...
Source: Drug Week (2005-11-18)
|
